S Bank Fund Management Ltd Has $6.16 Million Position in Johnson & Johnson $JNJ

Key Points

• S Bank Fund Management Ltd has reduced its stake in Johnson & Johnson (NYSE: JNJ) by 20.4%, now holding a position valued at approximately $6.16 million.
• Johnson & Johnson reported an EPS of $2.26 and revenue of $24.02 billion for the quarter ended August 30th, with analysts predicting a 10.58 EPS for the current fiscal year.
• The company declared a quarterly dividend of $1.30 per share, contributing to an annualized dividend yield of 2.7%, with the payment date set for December 9th.

S Bank Fund Management Ltd reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 20.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 40,296 shares of the company's stock after selling 10,302 shares during the quarter. Johnson & Johnson makes up 0.9% of S Bank Fund Management Ltd's investment portfolio, making the stock its 29th largest holding. S Bank Fund Management Ltd's holdings in Johnson & Johnson were worth $6,155,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Apexium Financial LP lifted its holdings in shares of Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after buying an additional 2,310 shares during the last quarter. Avanza Fonder AB lifted its holdings in shares of Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock worth $35,842,000 after buying an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC raised its stake in shares of Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its stake in shares of Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after purchasing an additional 4,816 shares in the last quarter. Finally, Absher Wealth Management LLC raised its stake in shares of Johnson & Johnson by 1.2% in the first quarter. Absher Wealth Management LLC now owns 215,584 shares of the company's stock valued at $35,752,000 after purchasing an additional 2,469 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $193.27 on Friday. The business's fifty day moving average price is $180.49 and its two-hundred day moving average price is $164.86. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The stock has a market capitalization of $465.45 billion, a price-to-earnings ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio is presently 50.19%.

Analyst Ratings Changes

A number of brokerages recently commented on JNJ. Royal Bank Of Canada restated an "outperform" rating and issued a $209.00 target price on shares of Johnson & Johnson in a research note on Friday, October 10th. Cowen restated a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research note on Wednesday. Finally, Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $199.59.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.